Fall in C-Peptide During First 2 Years From Diagnosis: Evidence of at Least Two Distinct Phases From Composite Type 1 Diabetes TrialNet Data

Benaroya Research Institute, Seattle, Washington, USA.
Diabetes (Impact Factor: 8.1). 06/2012; 61(8):2066-73. DOI: 10.2337/db11-1538
Source: PubMed


Interpretation of clinical trials to alter the decline in β-cell function after diagnosis of type 1 diabetes depends on a robust understanding of the natural history of disease. Combining data from the Type 1 Diabetes TrialNet studies, we describe the natural history of β-cell function from shortly after diagnosis through 2 years post study randomization, assess the degree of variability between patients, and investigate factors that may be related to C-peptide preservation or loss. We found that 93% of individuals have detectable C-peptide 2 years from diagnosis. In 11% of subjects, there was no significant fall from baseline by 2 years. There was a biphasic decline in C-peptide; the C-peptide slope was -0.0245 pmol/mL/month (95% CI -0.0271 to -0.0215) through the first 12 months and -0.0079 (-0.0113 to -0.0050) from 12 to 24 months (P < 0.001). This pattern of fall in C-peptide over time has implications for understanding trial results in which effects of therapy are most pronounced early and raises the possibility that there are time-dependent differences in pathophysiology. The robust data on the C-peptide obtained under clinical trial conditions should be used in planning and interpretation of clinical trials.

Download full-text


Available from: Paula Mcgee, Feb 16, 2015
  • Source
    • "Importantly, evidence for significant dysfunction of pancreatic beta cells is emerging from unpublished data from the new onset patients in the DiVid study [52] and from our own pancreas transplant recipients with disease recurrence, in which impaired beta cell function is shown despite the presence of insulin-positive cells at biopsy. These findings concur with recent reports showing that C-peptide secretion can persist in many patients, albeit at low levels, for several years after diagnosis [28•, 67•, 68•]. Altogether, these findings suggest the hypothesis that some patients might perhaps benefit from therapy to alter disease course or promote beta cell regeneration beyond just a few months after diagnosis; there is now a trend towards conducting clinical trials in patients with longer disease duration which will inform us as to whether there is indeed a wider window of therapeutic opportunity. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The Juvenile Diabetes Research Foundation (JDRF) Network for Pancreatic Organ Donors with Diabetes (JDRF nPOD) was established to obtain human pancreata and other tissues from organ donors with type 1 diabetes (T1D) in support of research focused on disease pathogenesis. Since 2007, nPOD has recovered tissues from over 100 T1D donors and distributed specimens to approximately 130 projects led by investigators worldwide. More recently, nPOD established a programmatic expansion that further links the transplantation world to nPOD, nPOD-Transplantation; this effort is pioneering novel approaches to extend the study of islet autoimmunity to the transplanted pancreas and to consent patients for postmortem organ donation directed towards diabetes research. Finally, nPOD actively fosters and coordinates collaborative research among nPOD investigators, with the formation of working groups and the application of team science approaches. Exciting findings are emerging from the collective work of nPOD investigators, which covers multiple aspects of islet autoimmunity and beta cell biology.
    Current Diabetes Reports 10/2014; 14(10):530. DOI:10.1007/s11892-014-0530-0 · 3.08 Impact Factor
  • Source
    • "Patients with chronic T1D show evidence of sustained beta cell apoptosis [65, 66], possibly suggesting that in patients with chronic T1D there is a continuous formation of new beta cells and that these cells subsequently go into apoptosis due to recurrent autoimmunity or other causes. The statement in one of the early papers [68] on residual beta cells in chronic T1D patients that ‘most patients whose pancreata still contain insulin cells after a diabetes duration of 10 to 20 years, will retain these insulin cells for the rest of their lives’ should therefore perhaps be modified to allow for the possibility that the residual beta cells are in fact newly formed cells that have escaped apoptosis. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Human type 1 diabetes (T1D) is considered to be an autoimmune disease, with CD8+ T-cell-mediated cytotoxicity being directed against the insulin-producing beta cells, leading to a gradual decrease in beta cell mass and the development of chronic hyperglycemia. The histopathologically defining lesion in recent-onset T1D patients is insulitis, a relatively subtle leucocytic infiltration present in approximately 10 % of the islets of Langerhans from children with recent-onset (<1 year) disease. Due to the transient nature of the infiltrate, its heterogeneous distribution in the pancreas and the nature of the patient population, material for research is extremely rare and limited to a cumulative total of approximately 150 cases collected over the past century. Most studies on the etiopathogenesis of T1D have therefore focused on the non-obese diabetic (NOD) mouse model, which shares many genetic and immunological disease characteristics with human T1D, although its islet histopathology is remarkably different. In view of these differences and in view of the limited success of clinical immune interventions based on observations in the NOD mouse, there is a renewed focus on studying the pathogenetic process in patient material.
    Seminars in Immunopathology 07/2014; 36(5). DOI:10.1007/s00281-014-0438-4 · 7.75 Impact Factor
  • Source
    • "We believe that the overall improved glycaemia reflects higher residual beta cell mass and if achieved in a human clinical trial would be reflected by the gold standard, an improved c-peptide response to a mixed meal tolerance test. [10] Therefore a brief course of rapamycin in conjunction with other immunomodulatory regimens, including but not limited to anti-CD3, is a rational strategy that deserves testing, especially since evidence from other clinical settings support its immunomodulatory effects. The worsening of blood glucose levels with rapid reversal implicates rapamycin to have a direct causal relationship to beta cells. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Non-Fc-binding Anti CD3 antibody has proven successful in reverting diabetes in the non-obese diabetes mouse model of type 1 diabetes and limited efficacy has been observed in human clinical trials. We hypothesized that addition of rapamycin, an mTOR inhibitor capable of inducing operational tolerance in allogeneic bone marrow transplantation, would result in improved diabetes reversal rates and overall glycemia. Seventy hyperglycemic non-obese diabetic mice were randomized to either a single injection of anti CD3 alone or a single injection of anti CD3 followed by 14 days of intra-peritoneal rapamycin. Mice were monitored for hyperglycemia and metabolic control. Mice treated with the combination of anti CD3 and rapamycin had similar rates of diabetes reversal compared to anti CD3 alone (25/35 vs. 22/35). Mice treated with anti CD3 plus rapamycin had a significant improvement in glycemia control as exhibited by lower blood glucose levels in response to an intra-peritoneal glucose challenge; average peak blood glucose levels 30 min post intra-peritoneal injection of 2 gr/kg glucose were 6.9 mmol/L in the anti CD3 plus rapamycin group vs. 10 mmo/L in the anti CD3 alone (P<0.05). The addition of rapamycin to anti CD3 results in significant improvement in glycaemia control in diabetic NOD mice.
    PLoS ONE 06/2013; 8(6):e67189. DOI:10.1371/journal.pone.0067189 · 3.23 Impact Factor
Show more